Marburg Ion-Beam Therapy Centre MIT

What Marburg Ion-Beam Therapy Centre MIT does

Marburg Ion-Beam Therapy Centre MIT is a specialized particle radiation therapy facility located on the Lahnberge campus in Marburg, Germany, operating as a private limited company (GmbH) wholly owned by RHÖN-KLINIKUM AG since August 2019, with medical responsibility held by the Universitätsklinikum Gießen und Marburg (UKGM). Founded in 2015, MIT is one of only two centers in Germany — and one of nine worldwide — licensed to deliver both proton and carbon ion (heavy ion) radiation therapy, serving oncology patients with radioresistant tumors, tumors adjacent to critical organs, pediatric malignancies, and cases requiring organ preservation. The facility operates four treatment rooms (three horizontal beam, one 45-degree angle) equipped with 6D robotic patient positioning systems enabling sub-millimeter accuracy.

MIT's technology platform centers on a synchrotron accelerator that propels ions to over 70% of light speed, combined with raster scanning beam delivery (up to 20x20 cm² coverage), intensity-modulated particle therapy (IMPT), and Bragg-peak dose distribution that maximizes tumor dose while sparing healthy tissue. Treatment courses typically run 20-30 fractions, with carbon ion therapy delivering up to 35% higher biological dose than conventional photon radiation and protons delivering up to 20% higher dose. The center has cumulatively treated more than 2,500 oncology patients across indications including brain tumors, head and neck tumors, prostate and pancreatic carcinomas, sarcomas, and pediatric tumors.

The business model is healthcare services revenue under the German statutory (GKV) and private insurance reimbursement system. Patients are acquired through UKGM outpatient clinic referrals, physician-to-physician referrals across Germany, and an International Office handling growing cross-border demand. Distribution is effectively direct-to-patient via clinical channels, with sales support through medical symposia (e.g., Marburger Kopf-Hals Symposium), peer-reviewed publications, and patient self-help group outreach. MIT is integrated within the Anneliese Pohl Comprehensive Cancer Center and the UCT Frankfurt-Marburg supraregional oncology network, and maintains research partnerships with Philipps-Universität Marburg, Justus-Liebig-Universität Gießen, THM Mittelhessen, GSI Helmholtzzentrum, DKFZ, and the European HITRIplus consortium. Commercial leadership is held by Managing Directors Dr. Sylvia Heinis and Hans-Jürgen Eckmann, with medical leadership under Prof. Dr. Sebastian Adeberg (since March 2023) and scientific/technical direction under Prof. Dr. Klemens Zink.

Name

Marburg Ion-Beam Therapy Centre MIT

Legal name

Marburger Ionenstrahl-Therapie Betriebs-Gesellschaft mbH

Website

https://mit-marburg.de

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Marburg Ion-Beam Therapy Centre MIT is a German specialized particle therapy facility offering proton and carbon ion radiation to oncology patients, operating four treatment rooms within RHÖN-KLINIKUM AG's hospital network and serving as one of only two such centers in Germany.

Ownership category

akta.pro rank

Product category

Radiation Oncology / Particle Therapy Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

akta.pro secondary industry

Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

• Particle therapy
• Proton radiation therapy
• Carbon ion therapy
• Oncology radiation treatment
• Heavy ion beam therapy

Headquarters

HQ city

Marburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Others

Revenue model

1. Healthcare Services Revenue: MIT operates as a specialized oncology treatment center within the German public healthcare system. Treatment is covered by statutory health insurance (GKV) and private insurance for eligible cancer patients. The center is part of UKGM's comprehensive cancer treatment offerings.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

The Marburg Ion-Beam Therapy Centre (MIT) is a specialized particle radiation therapy center offering proton therapy (using hydrogen ions) and carbon ion (heavy ion) therapy using a synchrotron-based accelerator and raster scanning beam delivery. The center operates four treatment rooms with robotic patient positioning and treats tumors that are difficult to address with conventional photon radiation, including radiation-resistant, hypoxic, and pediatric tumors. MIT is integrated within University Hospital Gießen and Marburg (UKGM) and is one of only two centers in Germany licensed to provide carbon ion therapy.

Product overview

The Marburg Ion-Beam Therapy Centre (MIT) is a specialized particle radiation therapy center offering two distinct radiation modalities: proton therapy (using hydrogen ions) and carbon ion therapy (using carbon-12 heavy ions). As one of only two centers in Germany offering carbon ion therapy, MIT provides treatments for complex, radiation-resistant, and deep-seated tumors. The facility operates four treatment rooms with robotic positioning systems and utilizes advanced technologies including raster scanning, Bragg-Peak delivery, and intensity-modulated particle therapy (IMPT). MIT is integrated into the University Hospital Gießen and Marburg (UKGM) and collaborates with Philipps-Universität Marburg and Technische Hochschule Mittelhessen for research. Treatment indications include pediatric tumors, brain tumors, head and neck tumors, prostate and pancreatic carcinomas, sarcomas, and recurrences of various malignancies.

Differentiator

Problem solved

Functional benefit

Brands

• MARS - Marburg Radiationtherapy Science Unit: Research unit focused on radiation therapy science

Products and services

• Proton Radiation Therapy Particle radiation therapy using positively charged hydrogen atoms (protons) accelerated to over three-quarters of light speed, enabling precise tumor targeting with minimal damage to surrounding healthy tissue through the Bragg-Peak effect. Designed for adult and pediatric oncology patients with tumors treatable via proton beams.
• Carbon Ion Radiation Therapy Advanced particle radiation therapy using carbon-12 ions (C-12) that provides higher biological effectiveness than protons or photons, making it particularly effective for radiation-resistant tumors, hypoxic cells, and slow-growing tumors. For adult oncology patients with tumors that cannot be adequately treated with photons or protons.
• Pediatric Particle Therapy Specialized radiation treatment for children with cancer offering reduced dose exposure to healthy tissue, lower risk of secondary malignancies, and avoidance of growth and development deficits. Includes treatment of brain tumors, sarcomas, Hodgkin lymphomas, neuroblastomas, germ cell tumors, and craniopharyngiomas.
• Boost Therapy (Combined Photon-Particle Treatment) Combined treatment approach where particle therapy supplements conventional photon radiation, with particle beams delivering a concentrated dose boost to the tumor while photon therapy covers broader areas. Used for oncology patients requiring optimized tumor control with managed toxicity.

Quantifiable outcome

• Up to 35% higher radiation dose compared to conventional photon therapy with carbon ions, up to 20% higher with protons
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered primary, core and strategic.

• RHÖN-KLINIKUM AGprimaryStrategic or Co-development Partner · 1 August 2019RHÖN-KLINIKUM AG assumed sole operational responsibility for MIT on August 1, 2019, taking over from University Hospital Heidelberg. The company secured the long-term operation of the facility and continues to invest in expanding treatment offerings. UKGM maintains medical responsibility for patient treatment.
• Philipps-Universität MarburgcoreStrategic or Co-development PartnerAcademic partnership with the Medical Faculty (Fachbereich 20 – Medizin) for research collaboration, joint doctoral programs, and clinical research. Dr. Kilian Baumann completed a cooperative doctorate through this partnership.
• Justus-Liebig-Universität GießencoreStrategic or Co-development PartnerAcademic partnership with the Medical Faculty (Fachbereich 11 – Medizin) as part of the Universitätsklinikum Gießen und Marburg (UKGM) structure for integrated medical education and research.
• Universitätsklinikum Gießen und Marburg (UKGM)primaryStrategic or Co-development PartnerUKGM provides medical leadership and patient care under Prof. Dr. Sebastian Adeberg. The Department of Radiology and Radiooncology handles patient referrals, treatment planning, and follow-up care, while MIT provides the specialized particle therapy technology.
• University Center for Tumor Diseases (UCT) Frankfurt-MarburgcoreStrategic or Co-development PartnerMIT is a treatment partner within the UCT Frankfurt-Marburg, a supraregional oncology center of excellence funded by German Cancer Aid with 4.2 million euros. The center coordinates comprehensive cancer care across multiple disciplines.
• Anneliese Pohl Comprehensive Cancer CentercoreStrategic or Co-development PartnerMIT serves as a treatment partner in this certified comprehensive cancer center at University Hospital Marburg, participating in all organ centers certified by the German Cancer Society.
• HITRIplus ConsortiumstrategicStrategic or Co-development PartnerHeavy Ion Therapy Research Integration plus (HITRIplus) is a European research collaboration led by Professor Marco Durante and clustered by CNAO in Pavia, Italy. MIT contributes to advancing heavy ion therapy research.
• German Cancer Research Center (DKFZ)strategicTechnology or IntegrationCollaboration on the gROS project developing GPU-based Monte Carlo code to model the chemical phase of radiation effects, particularly the role of oxygen in Reactive Oxygen Species production.
• GSI Helmholtzzentrum für SchwerionenforschungstrategicTechnology or IntegrationCollaboration through the PARTITUR project investigating carbon beam effectiveness for lung tumors, focusing on biological aspects like signaling, targeting, and range modulators.
• Technische Hochschule Mittelhessen (THM)coreStrategic or Co-development PartnerStrong research partnership including the LOEWE-Schwerpunkt ADMIT project. Prof. Dr. Kilian Baumann holds a W2 professorship at THM while continuing clinical work at MIT, strengthening collaboration between academic research and clinical practice.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• CNAO (Centro Nazionale di Adroterapia Oncologica): Italian national center for hadrontherapy providing both proton and carbon ion therapy. Direct peer in technology platform, clinical scope, and research consortium leadership (CNAO leads the HITRIplus cluster in which MIT participates).
• MedAustron: Austrian ion beam therapy center offering proton and carbon ion therapy with comparable clinical infrastructure. Direct peer as one of few European centers with dual-modality capability and similar treatment programs.
• Heidelberg Ion-Beam Therapy Center (HIT): Operated by Universitätsklinikum Heidelberg, HIT is the other German center offering both proton and carbon ion therapy. Most direct peer globally due to identical dual-modality treatment, similar patient populations, and shared German regulatory/reimbursement context.

Broad incumbents

• Ion Beam Applications (IBA): World leader in proton therapy equipment manufacturing (ProteusONE, ProteusPLUS). Indirect peer as the dominant proton therapy equipment supplier that shapes the competitive landscape in which MIT operates.
• National Cancer Center Japan: Japan is the global pioneer of carbon ion therapy with multiple centers (NCC, Gunma, Hyogo). NCC operates heavy ion therapy and serves as a benchmark for clinical evidence generation and treatment protocols in particle therapy.
• Elekta: Global provider of radiation therapy and radiosurgery equipment, primarily LINAC-based photon systems and Gamma Knife. Competes broadly in radiation oncology alongside particle therapy centers like MIT.
• Varian (a Siemens Healthineers company): Major manufacturer of radiation therapy equipment including the ProBeam proton therapy system used in particle therapy centers. Adjacent incumbent providing the technology infrastructure underpinning MIT's synchrotron-based operations.

Regional players

• Provision Healthcare (Provision CARES Proton Therapy): US-based operator of proton-only therapy centers. Regional peer in North America offering advanced particle therapy but limited to proton modality, complementing rather than directly competing with MIT's European operations.
• Shanghai Proton and Heavy Ion Center: China's first integrated proton and heavy ion therapy facility using comparable technology. Regional peer in Asia offering similar dual-modality treatment to MIT, but operating in a different geographic market.
• Northwestern Medicine Proton Center: US-based proton therapy center affiliated with Northwestern Medicine providing proton-only treatment. Regional peer in North America with similar referral-driven academic hospital model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mitparticletherapycenter

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marburg Ion-Beam Therapy Centre MIT